SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.065+1.2%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (47)7/29/1997 12:35:00 PM
From: Haolin Ni   of 645
 
Hi, Rick,

I wonder your profession. It seems you know a lot about the vaccine but how can you say it is undervalued when you don't know the productions cost, profit margin. you don't willing say AVIR has no patent in their vaccine production. What about the future competition.

As a profrssional in stock market, he will certainlynot to buy AVIR after it has increased over 200% after the news and the posible earning is still two years away.

Please read the charters of biotech companies, every one has its peak after the news but it is not sustainable since it has no earning to support the valuation. I am sure the market maker will manipulate the price before the secondary offering when the volune of AVIR is low, particularly at current market situation. I belive you notice the market is overvalued now. It is not the good time to commite for the long term investment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News